| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 47 | 2024 | 367 | 9.630 |
Why?
|
| Cystectomy | 20 | 2024 | 110 | 3.570 |
Why?
|
| Carcinoma, Transitional Cell | 10 | 2022 | 152 | 2.230 |
Why?
|
| Prostatic Neoplasms | 11 | 2019 | 1757 | 1.340 |
Why?
|
| Prostate | 5 | 2024 | 410 | 1.230 |
Why?
|
| Metabolic Syndrome | 2 | 2024 | 125 | 1.210 |
Why?
|
| Phototherapy | 2 | 2019 | 35 | 1.200 |
Why?
|
| Prostatectomy | 7 | 2013 | 476 | 1.030 |
Why?
|
| Organ Transplantation | 4 | 2024 | 286 | 0.990 |
Why?
|
| ErbB Receptors | 3 | 2019 | 499 | 0.970 |
Why?
|
| Robotics | 7 | 2013 | 269 | 0.960 |
Why?
|
| Postoperative Complications | 8 | 2024 | 2348 | 0.910 |
Why?
|
| Lymph Node Excision | 6 | 2017 | 222 | 0.890 |
Why?
|
| Antineoplastic Agents | 8 | 2020 | 2347 | 0.800 |
Why?
|
| BCG Vaccine | 3 | 2024 | 35 | 0.750 |
Why?
|
| Urinary Diversion | 2 | 2018 | 42 | 0.700 |
Why?
|
| Urogenital Neoplasms | 4 | 2024 | 24 | 0.680 |
Why?
|
| Humans | 70 | 2024 | 91074 | 0.650 |
Why?
|
| Urothelium | 3 | 2022 | 64 | 0.650 |
Why?
|
| Clinical Trials as Topic | 6 | 2024 | 1144 | 0.630 |
Why?
|
| Aged | 29 | 2024 | 19574 | 0.610 |
Why?
|
| Ureteroscopy | 1 | 2018 | 38 | 0.600 |
Why?
|
| Immunotherapy | 3 | 2020 | 702 | 0.600 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2017 | 13 | 0.590 |
Why?
|
| Administration, Intravesical | 5 | 2024 | 34 | 0.580 |
Why?
|
| Androgens | 2 | 2011 | 175 | 0.570 |
Why?
|
| Carcinoma | 3 | 2015 | 438 | 0.570 |
Why?
|
| Prostate-Specific Antigen | 3 | 2010 | 343 | 0.570 |
Why?
|
| Ureteral Obstruction | 1 | 2018 | 69 | 0.570 |
Why?
|
| Paraganglioma | 1 | 2017 | 15 | 0.560 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 255 | 0.550 |
Why?
|
| Biomedical Research | 1 | 2021 | 401 | 0.550 |
Why?
|
| Middle Aged | 31 | 2024 | 26555 | 0.550 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 47 | 0.550 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 278 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2024 | 1374 | 0.540 |
Why?
|
| Testosterone | 2 | 2011 | 272 | 0.540 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2013 | 99 | 0.520 |
Why?
|
| Neoplasm Invasiveness | 10 | 2024 | 570 | 0.510 |
Why?
|
| Male | 39 | 2024 | 43249 | 0.510 |
Why?
|
| Radiotherapy | 1 | 2017 | 321 | 0.510 |
Why?
|
| Cell Proliferation | 3 | 2017 | 1695 | 0.510 |
Why?
|
| Metastasectomy | 1 | 2015 | 9 | 0.500 |
Why?
|
| Urologists | 3 | 2024 | 34 | 0.500 |
Why?
|
| Lymph Nodes | 3 | 2020 | 554 | 0.500 |
Why?
|
| Proteomics | 1 | 2017 | 242 | 0.480 |
Why?
|
| Pyrimidines | 1 | 2017 | 372 | 0.480 |
Why?
|
| Cystoscopy | 4 | 2024 | 38 | 0.470 |
Why?
|
| Histones | 1 | 2017 | 345 | 0.470 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 2615 | 0.450 |
Why?
|
| Anilides | 3 | 2024 | 45 | 0.440 |
Why?
|
| Medical Oncology | 4 | 2024 | 390 | 0.440 |
Why?
|
| Time Factors | 8 | 2024 | 5378 | 0.440 |
Why?
|
| Retrospective Studies | 17 | 2024 | 9400 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 3500 | 0.430 |
Why?
|
| Lymphatic Metastasis | 6 | 2020 | 500 | 0.410 |
Why?
|
| Urology | 4 | 2024 | 124 | 0.410 |
Why?
|
| Urinary Bladder | 4 | 2024 | 249 | 0.390 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 492 | 0.390 |
Why?
|
| Pyridines | 3 | 2024 | 304 | 0.390 |
Why?
|
| Deficiency Diseases | 1 | 2011 | 12 | 0.370 |
Why?
|
| Female | 26 | 2024 | 47186 | 0.360 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 53 | 0.340 |
Why?
|
| Neoplasms | 2 | 2024 | 3053 | 0.330 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2024 | 478 | 0.330 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1559 | 0.320 |
Why?
|
| Infrared Rays | 2 | 2019 | 17 | 0.300 |
Why?
|
| Photosensitizing Agents | 2 | 2019 | 51 | 0.300 |
Why?
|
| Neoplasm Staging | 7 | 2018 | 2022 | 0.290 |
Why?
|
| Mice, Nude | 3 | 2019 | 821 | 0.280 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 38 | 0.280 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 526 | 0.270 |
Why?
|
| Ipilimumab | 2 | 2024 | 60 | 0.270 |
Why?
|
| SEER Program | 2 | 2017 | 202 | 0.270 |
Why?
|
| Population Surveillance | 1 | 2007 | 209 | 0.270 |
Why?
|
| Cryptorchidism | 1 | 2006 | 12 | 0.260 |
Why?
|
| Urologic Neoplasms | 2 | 2020 | 74 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 387 | 0.250 |
Why?
|
| Succinate Dehydrogenase | 2 | 2015 | 16 | 0.250 |
Why?
|
| Paraganglioma, Extra-Adrenal | 2 | 2015 | 11 | 0.250 |
Why?
|
| Prognosis | 8 | 2020 | 3825 | 0.250 |
Why?
|
| Testis | 1 | 2006 | 152 | 0.250 |
Why?
|
| Testicular Neoplasms | 1 | 2006 | 115 | 0.240 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2021 | 159 | 0.240 |
Why?
|
| Risk Factors | 7 | 2024 | 5608 | 0.240 |
Why?
|
| Hypogonadism | 1 | 2005 | 40 | 0.230 |
Why?
|
| Consensus | 3 | 2020 | 374 | 0.230 |
Why?
|
| Biopsy | 4 | 2014 | 1196 | 0.230 |
Why?
|
| Certification | 1 | 2024 | 64 | 0.230 |
Why?
|
| Germ-Line Mutation | 3 | 2015 | 352 | 0.220 |
Why?
|
| Hematuria | 1 | 2024 | 50 | 0.220 |
Why?
|
| Postoperative Care | 1 | 2024 | 235 | 0.210 |
Why?
|
| Treatment Outcome | 10 | 2024 | 8436 | 0.210 |
Why?
|
| Transplant Recipients | 1 | 2024 | 147 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 1404 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 2550 | 0.200 |
Why?
|
| Health Care Sector | 1 | 2021 | 14 | 0.190 |
Why?
|
| Adult | 16 | 2024 | 27147 | 0.190 |
Why?
|
| United States | 10 | 2024 | 7188 | 0.190 |
Why?
|
| Equipment and Supplies | 1 | 2021 | 28 | 0.190 |
Why?
|
| Autocrine Communication | 1 | 2021 | 21 | 0.190 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 6847 | 0.190 |
Why?
|
| Conflict of Interest | 1 | 2021 | 68 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2019 | 4367 | 0.180 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 201 | 0.180 |
Why?
|
| Publishing | 1 | 2021 | 91 | 0.180 |
Why?
|
| History, 21st Century | 1 | 2021 | 185 | 0.180 |
Why?
|
| Neoplasm Grading | 3 | 2024 | 376 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2024 | 2345 | 0.170 |
Why?
|
| Forecasting | 1 | 2021 | 307 | 0.170 |
Why?
|
| Survival Rate | 4 | 2020 | 1898 | 0.170 |
Why?
|
| History, 20th Century | 1 | 2021 | 316 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 427 | 0.170 |
Why?
|
| Ferrosoferric Oxide | 1 | 2019 | 19 | 0.170 |
Why?
|
| Lymphography | 1 | 2019 | 27 | 0.170 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2019 | 17 | 0.160 |
Why?
|
| Incidence | 3 | 2022 | 1599 | 0.160 |
Why?
|
| Animals | 7 | 2021 | 27783 | 0.160 |
Why?
|
| Trastuzumab | 1 | 2019 | 77 | 0.150 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 45 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1295 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 136 | 0.150 |
Why?
|
| Physicians | 2 | 2017 | 691 | 0.150 |
Why?
|
| Awareness | 1 | 2018 | 89 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2018 | 99 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 333 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 164 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2020 | 200 | 0.140 |
Why?
|
| Resorcinols | 1 | 2017 | 5 | 0.140 |
Why?
|
| Isoindoles | 1 | 2017 | 14 | 0.140 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 12 | 0.140 |
Why?
|
| Benzodioxoles | 1 | 2017 | 14 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2021 | 882 | 0.140 |
Why?
|
| Epigenomics | 1 | 2018 | 103 | 0.140 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 532 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 342 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2017 | 234 | 0.140 |
Why?
|
| Isoxazoles | 1 | 2017 | 77 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2017 | 1500 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 111 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 355 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 73 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 245 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 184 | 0.130 |
Why?
|
| Mice | 4 | 2021 | 11993 | 0.130 |
Why?
|
| Triazoles | 1 | 2017 | 107 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 91 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2017 | 118 | 0.130 |
Why?
|
| Imidazoles | 1 | 2017 | 139 | 0.130 |
Why?
|
| Intraoperative Care | 1 | 2017 | 85 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 85 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 210 | 0.130 |
Why?
|
| Melanoma | 1 | 2020 | 475 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2017 | 294 | 0.130 |
Why?
|
| Cell Division | 1 | 2017 | 692 | 0.130 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 1713 | 0.130 |
Why?
|
| Benzamides | 1 | 2017 | 237 | 0.130 |
Why?
|
| Erectile Dysfunction | 2 | 2024 | 76 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2017 | 520 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 365 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 181 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 756 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 309 | 0.120 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 19 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 341 | 0.120 |
Why?
|
| Hospitals, High-Volume | 2 | 2013 | 38 | 0.120 |
Why?
|
| Disease Progression | 2 | 2018 | 1493 | 0.120 |
Why?
|
| Muir-Torre Syndrome | 1 | 2014 | 4 | 0.120 |
Why?
|
| Facial Neoplasms | 1 | 2014 | 25 | 0.120 |
Why?
|
| Cell Survival | 1 | 2017 | 984 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 854 | 0.120 |
Why?
|
| Ureteral Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 405 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 396 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 297 | 0.110 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 982 | 0.110 |
Why?
|
| Muscles | 1 | 2014 | 192 | 0.110 |
Why?
|
| Logistic Models | 3 | 2013 | 1216 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1806 | 0.110 |
Why?
|
| Hospitals | 2 | 2013 | 309 | 0.110 |
Why?
|
| Hospital Administration | 1 | 2013 | 26 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2018 | 672 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1248 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1935 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2017 | 3442 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 591 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1465 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 282 | 0.100 |
Why?
|
| Hypertension | 2 | 2020 | 757 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2012 | 175 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2012 | 107 | 0.090 |
Why?
|
| Michigan | 1 | 2011 | 53 | 0.090 |
Why?
|
| Length of Stay | 2 | 2013 | 758 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 327 | 0.090 |
Why?
|
| Child | 4 | 2015 | 7273 | 0.090 |
Why?
|
| Urologic Surgical Procedures | 1 | 2012 | 150 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 360 | 0.090 |
Why?
|
| Organ Sparing Treatments | 2 | 2024 | 47 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 397 | 0.090 |
Why?
|
| Medicare | 3 | 2022 | 432 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 1750 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 306 | 0.080 |
Why?
|
| Preoperative Period | 1 | 2010 | 95 | 0.080 |
Why?
|
| Infant | 2 | 2006 | 3204 | 0.080 |
Why?
|
| Ilium | 1 | 2009 | 18 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2006 | 3790 | 0.080 |
Why?
|
| Disclosure | 2 | 2021 | 109 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2785 | 0.080 |
Why?
|
| Reoperation | 1 | 2011 | 611 | 0.080 |
Why?
|
| Drainage | 1 | 2009 | 169 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 2375 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 439 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2711 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 667 | 0.070 |
Why?
|
| Nephrectomy | 2 | 2024 | 295 | 0.070 |
Why?
|
| Drug Design | 1 | 2007 | 129 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 852 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 432 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2021 | 368 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 354 | 0.060 |
Why?
|
| Biomechanical Phenomena | 1 | 2006 | 483 | 0.060 |
Why?
|
| Physician Assistants | 1 | 2024 | 21 | 0.060 |
Why?
|
| Capecitabine | 1 | 2024 | 93 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2013 | 1073 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1609 | 0.050 |
Why?
|
| Adolescent | 3 | 2015 | 9411 | 0.050 |
Why?
|
| Europe | 2 | 2013 | 329 | 0.050 |
Why?
|
| Financial Statements | 1 | 2021 | 3 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2022 | 153 | 0.050 |
Why?
|
| Age Factors | 1 | 2006 | 1876 | 0.050 |
Why?
|
| Professional Misconduct | 1 | 2021 | 25 | 0.050 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 7 | 0.050 |
Why?
|
| Urinary Incontinence | 1 | 2024 | 216 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 599 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 53 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2021 | 41 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2020 | 4 | 0.050 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2021 | 72 | 0.040 |
Why?
|
| Apoptosis | 1 | 2007 | 1723 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 99 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 6502 | 0.040 |
Why?
|
| Hepatitis | 1 | 2020 | 34 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2020 | 28 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 58 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 183 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2020 | 46 | 0.040 |
Why?
|
| RNA Interference | 1 | 2021 | 378 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.040 |
Why?
|
| Fatigue | 1 | 2020 | 175 | 0.040 |
Why?
|
| Diarrhea | 1 | 2020 | 178 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 557 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 988 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 3716 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 608 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 281 | 0.040 |
Why?
|
| Patient Selection | 2 | 2015 | 685 | 0.040 |
Why?
|
| Urethra | 1 | 2018 | 116 | 0.040 |
Why?
|
| Colitis | 1 | 2020 | 251 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 169 | 0.040 |
Why?
|
| Drug Industry | 1 | 2017 | 54 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 64 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 613 | 0.030 |
Why?
|
| Pelvis | 1 | 2017 | 96 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 353 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 803 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 483 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 759 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 243 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 40 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 78 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 594 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 817 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 35 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 360 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 62 | 0.030 |
Why?
|
| Checklist | 1 | 2015 | 66 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 244 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 58 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 56 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 184 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 338 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2013 | 33 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2891 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 176 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2013 | 19 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 102 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 118 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 785 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 303 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 164 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2013 | 185 | 0.020 |
Why?
|
| Luminescence | 1 | 2010 | 20 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 681 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2012 | 126 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 211 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1877 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2020 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 316 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 594 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 367 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 17 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2007 | 23 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 67 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 4203 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1892 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 475 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2007 | 269 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 402 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2682 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1063 | 0.020 |
Why?
|
| Hypoxia | 1 | 2010 | 660 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 1169 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2416 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 284 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2004 | 139 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 968 | 0.010 |
Why?
|